Features
Complement Inhibition in Geographic Atrophy
Trial data herald another new era in AMD treatment.
By William Carrera, MD, MS, Jeffrey S. Heier, MD
Current Terminology for Geographic Atrophy Pathology
Efforts aim to dispel confusion as potential treatments approach.
By Glenn J. Jaffe, MD
Imaging Modalities for Geographic Atrophy
A variety of tools are available to identify atrophy and monitor progression.
By Sheena Khanna, MD, Jordan A. Sugarman, MD, SriniVas R. Sadda, MD
Treatment of Geographic Atrophy by Anatomic Location
Complement inhibitors could slow progression in lesions with and without subfoveal involvement.
By Anna Marmalidou, MD, Antonio Yaghy, MD, Nadia K. Waheed, MD, MPH
Novel Targets for Geographic Atrophy
Several agents are under investigation.
By Rishi P. Singh, MD, Neha Sharma, MD, MPH
The Patient Perspective on Geographic Atrophy
Education and relationship building will be key to successful treatment.
By Nancy M. Holekamp, MD
Practice Considerations Regarding Treatment of Geographic Atrophy
Many aspects of retina practice will change if new treatments become available.
By Daniel Su, MD, David S. Boyer, MD
Departments
UPFRONT: Evolution of Retina Clinical Trials to Target Geographic Atrophy
By Peter K. Kaiser, MD
GUEST EDITORIAL: At the Brink of a Dry AMD Revolution
New potential treatments for GA could begin a paradigm shift in retina.
By Eleonora Lad, MD, PhD
UVEITIS CORNER: Update on Topical and Local Steroid Treatments for Uveitis
Physicians can choose among various administration routes.
By Roxana A. Hojjatie, BS, Sruthi Arepalli, MD
NEW PRODUCT APPLICATIONS: Platform Combines Multiple Testing Modalities Into One Device
Improving workflow, and saving time and space, are just some of its perks.
By Karen Appold, contributing writer
CONTROVERSIES IN CARE: DRCR Network Protocol AC on Step Therapy in Retinal Disease
The high cost of drugs in the United States has become a major issue.
By Michael Colucciello, MD, Reginald Sanders, MD
News
SUBSPECIALTY NEWS: Methotrexate for vitreoretinal lymphoma, drugs for retinitis pigmentosa, AI technology in retina, and more.
By Rochelle Nataloni, contributing writer